The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 26, 2013
Filed:
Feb. 01, 2006
John T. Schiller, Kensington, MD (US);
Diana V. Pastrana, McLean, VA (US);
Richard B. S. Roden, Severna Park, MD (US);
Ratish Gambhira, Mandeville, LA (US);
Douglas R. Lowy, Bethesda, MD (US);
John T. Schiller, Kensington, MD (US);
Diana V. Pastrana, McLean, VA (US);
Richard B. S. Roden, Severna Park, MD (US);
Ratish Gambhira, Mandeville, LA (US);
Douglas R. Lowy, Bethesda, MD (US);
The United States of America, as represented by the Secretary, Department of Health and Human Services, Washington, DC (US);
The Johns Hopkins University, Baltimore, MD (US);
Abstract
The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein or peptide other than a papillomavirus L2 protein or peptide.